C
Christine Campbell
Researcher at Shire plc
Publications - 21
Citations - 1551
Christine Campbell is an academic researcher from Shire plc. The author has contributed to research in topics: Breast cancer & Trastuzumab. The author has an hindex of 12, co-authored 21 publications receiving 826 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew Tutt,Judy Garber,Bella Kaufman,Giuseppe Viale,Debora Fumagalli,Priya Rastogi,Priya Rastogi,Richard D. Gelber,Evandro de Azambuja,Anitra Fielding,Judith Balmaña,Susan M. Domchek,Karen A. Gelmon,Simon J. Hollingsworth,Larissa A. Korde,Barbro Linderholm,Hanna Bandos,Hanna Bandos,Elżbieta Senkus,Jennifer Marie Suga,Zhimin Shao,Andrew W. Pippas,Zbigniew Nowecki,Tomasz Huzarski,Patricia A. Ganz,Peter Lucas,Peter Lucas,Nigel Baker,Sibylle Loibl,Robin McConnell,Martine Piccart,Rita K. Schmutzler,Guenther G. Steger,Joseph P. Costantino,Amal Arahmani,Norman Wolmark,Norman Wolmark,Eleanor McFadden,Vassiliki Karantza,Sunil R. Lakhani,Greg Yothers,Greg Yothers,Christine Campbell,Charles E. Geyer +43 more
TL;DR: In this paper, a poly(adenosine diphosphate-ribose) polymerase inhibitor was proposed to target cancers with defects in homologous recombination repair by synthetic lethality.
Journal ArticleDOI
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado,Carsten Denkert,Christine Campbell,Peter Savas,Paolo Nuciforo,Claudia Aura,Evandro de Azambuja,Holger Eidtmann,Catherine E. Ellis,José Baselga,Martine Piccart-Gebhart,Stefan Michiels,Ian Bradbury,Christos Sotiriou,Sherene Loi +14 more
TL;DR: The presence of TILs at diagnosis is an independent, positive, prognostic marker in HER2-positive early breast cancer treated with neoadjuvant anti-HER2 agents and chemotherapy for both pCR and EFS end points.
Journal ArticleDOI
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials
Ciara C. O’Sullivan,Ian Bradbury,Christine Campbell,Marc Spielmann,Edith A. Perez,Heikki Joensuu,Joseph P. Costantino,Suzette Delaloge,Priya Rastogi,Dimitrios Zardavas,Karla V. Ballman,Eileen Holmes,Evandro de Azambuja,Martine Piccart-Gebhart,Jo Anne Zujewski,Richard D. Gelber +15 more
TL;DR: Women with small (≤ 2 cm) human epidermal growth factor receptor 2 (HER2) -positive breast cancer treated in randomized trastuzumab trials derived substantial DFS and OS benefit from adjuvant trastzumab.
Journal ArticleDOI
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini,Christine Campbell,José Bines,Larissa A. Korde,Miguel Izquierdo,Debora Fumagalli,Lucia Del Mastro,Michail Ignatiadis,Kathleen I. Pritchard,Antonio C. Wolff,Christian Jackisch,István Láng,Michael Untch,Ian E. Smith,Frances M. Boyle,Binghe Xu,Carlos H. Barrios,José Baselga,Alvaro Moreno-Aspitia,Martine Piccart,Richard D. Gelber,Evandro de Azambuja +21 more
TL;DR: In this unplanned analysis, no association between TRA rate and type of anti-HER2 treatment was observed, and TRA was associated with statistically significant survival benefits in premenopausal hormone receptor-positive/HER2-positive early breast cancer patients.
Journal ArticleDOI
High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Maurizio Scaltriti,Paolo Nuciforo,Ian Bradbury,Jeff Sperinde,Dominique Agbor-Tarh,Christine Campbell,Ahmed Chenna,John Winslow,Violeta Serra,Josep Lluis Parra,Ludmila Prudkin,Jose Jimenez,Claudia Aura,Nadia Harbeck,Lajos Pusztai,Catherine E. Ellis,Holger Eidtmann,Joaquín Arribas,Javier Cortes,Evandro de Azambuja,Martine Piccart,José Baselga +21 more
TL;DR: Investigating whether the levels of p95HER2 and HER2 can predict response to anti-HER2 therapy in patients with breast cancer found high levels of these markers were predictive for pCR, especially in the hormone receptor (HR)–positive subset of patients.